More on HLS
Data
Financials
News
Click line-items for a historical chart and %
| Net income | 236M |
| Income from discontinued operations | 300K |
| Provision for doubtful accounts | 46.7M |
| Provision for government, class action, and related settlements | |
| Depreciation and amortization | 128.8M |
| (Gain) loss on interest rate swaps | |
| Loss on early extinguishment of debt | 7.4M |
| Equity in net income of nonconsolidated affiliates | -7.3M |
| Distributions from nonconsolidated affiliates | 5.9M |
| Stock-based compensation | 17.4M |
| Deferred tax expense | 110.6M |
| Other | |
| Accounts receivable | -75.7M |
| Other assets | -4.4M |
| Income tax refund receivable | |
| Accounts payable | 1.9M |
| Accrued interest | 6M |
| Other liabilities | 11.8M |
| Premium received on bond issuance | |
| Premium paid on redemption of bonds | |
| Refunds due patients and other third-party payors | |
| Government, class action, and related settlements | |
| Net cash provided by operating activities of discontinued operations | -600K |
| Total adjustments | 253.2M |
| Net cash provided by operating activities | 489.5M |
| Capital expenditures | -113.9M |
| Acquisition of a business, net of cash acquired | -19.6M |
| Purchase of restricted investments | -800K |
| Proceeds from sale of restricted investments | |
| Net change in restricted cash | -7.1M |
| Net settlements on interest rate swaps | |
| Other | 2.6M |
| Net cash (used in) provided by investing activities of discontinued operations | |
| Net cash used in investing activities | -156.3M |
| Principal borrowings on term loan | 0 |
| Proceeds from bond issuance | 0 |
| Principal payments on debt, including pre-payments | |
| Borrowings on revolving credit facility | 260M |
| Payments on revolving credit facility | -240M |
| Principal payments under capital lease obligations | |
| Debt issue costs | 0 |
| Dividends paid on convertible perpetual preferred stock | |
| Distributions paid to noncontrolling interests of consolidated affiliates | |
| Other | -7.2M |
| Net cash used in financing activities | -318.4M |
| Increase in cash and cash equivalents | 14.8M |
| Cash and cash equivalents at beginning of period | 61.6M |
| Less: Cash and cash equivalents of facilities held for sale at end of period | |
| Cash and cash equivalents at end of period | 76.4M |
Entities mentioned with HLS
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- JPMorgan | View Related Stories »
- Trading Radar | View Related Stories »
- Citi | View Related Stories »
- 13G | View Related Stories »
- Glenview Capital Management | View Related Stories »
- Show More...
